The World Health Organization (WHO) has designated a Singapore-based research network as a collaborating centre to enhance the quality of clinical research in the region. This initiative aims to address both current and future public health challenges effectively.
ADVANCE-ID’s Mission
Advancing Clinical Evidence in Infectious Diseases (ADVANCE-ID) has joined a select group of WHO collaborating centres worldwide. Its primary mission is to support the global health programmes and strategic priorities of the WHO. As Singapore’s 13th collaborating centre, ADVANCE-ID is committed to improving the regional research ecosystem and collaborating with other nations to prevent, detect, and control infectious diseases.
Improving Research Standards
The network aims to elevate research standards and accelerate the generation of scientific evidence. By enhancing disease control and reducing infection rates in neighboring countries, the initiative strives to protect Singapore’s population from emerging health threats that may arise across borders.
Collaborative Efforts
During the official announcement of the WHO appointment on August 31, Mo Yin, director of ADVANCE-ID, emphasized the value of collaboration. He stated, “By working together, our partners gain access to Singapore’s clinical trial expertise, while Singapore benefits from the scale, diversity, experience, and expertise of our regional partners.” This partnership model enables the answering of pressing questions that no single nation could address independently.
Unique Focus on Antimicrobial Resistance
ADVANCE-ID operates under the National University of Singapore’s Saw Swee Hock School of Public Health and is unique as the only international network focusing on antimicrobial resistance (AMR). In addition to its work on AMR, the centre will broaden its capabilities to encompass other infectious disease priorities.
Expanding Capabilities
Mo Yin noted that the skills being developed—such as trial design, implementation, capacity building, and rapid site activation—will be applicable to a wider range of health threats over time. The goal is to support WHO initiatives and help countries in the region tackle emerging challenges effectively.
Recognition and Future Goals
Officially designated on April 28, ADVANCE-ID is the first WHO collaborating centre in the Western Pacific region dedicated to clinical trials. Its appointment is not only a milestone for Singapore but also a recognition of the network’s contributions to both regional and global public health.
A Strategic Location
Launched in March 2022, ADVANCE-ID connects over 30 hospitals across Asia to collaborate on infectious disease clinical research. Given the high incidence of AMR-related deaths in Asia, the network’s strategic location in Singapore is vital for conducting clinical trials aimed at developing new antibiotics and preventive strategies.
Collaborating with Local Institutions
The network collaborates with all three medical schools in Singapore, engaging investigators and institutions across various public healthcare clusters. It also receives support from the National Centre for Infectious Diseases and the Communicable Diseases Agency, further strengthening its research capabilities.
Engaging Policymakers
Mo Yin highlighted the importance of engaging with policymakers to ensure that clinical trials and scientific evidence effectively influence health policy. The WHO appointment provides ADVANCE-ID with more avenues to connect with government officials and stakeholders.
In conclusion, ADVANCE-ID’s designation as a WHO collaborating centre marks a significant advancement in regional health research. By fostering collaboration and enhancing research capabilities, it aims to address critical public health challenges and contribute to global health initiatives. The future looks promising as this network continues to evolve and make impactful contributions to the field of infectious diseases.
- Key Takeaways:
- ADVANCE-ID is Singapore’s 13th WHO collaborating centre focused on clinical trials.
- The network aims to improve research standards and address public health challenges.
- Collaboration with regional partners enhances Singapore’s clinical trial expertise.
- The focus on antimicrobial resistance positions ADVANCE-ID uniquely in the global research landscape.
- Engaging policymakers is crucial for influencing health policy based on scientific evidence.
Read more → www.straitstimes.com